Travere Therapeutics (TVTX) Accumulated Expenses (2011 - 2026)

Travere Therapeutics' Accumulated Expenses history runs 16 years deep, the most recent figure standing at $104.4 million for Q1 2026.

• Quarterly Accumulated Expenses rose 35.4% year-over-year to $104.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.4 million (up 35.4% YoY) and the FY2025 annual result came in at $126.0 million, up 46.5% from the prior year.
• Accumulated Expenses was $104.4 million for Q1 2026 at Travere Therapeutics, down from $126.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $139.6 million in Q1 2024 and bottomed at $69.2 million in Q1 2022.
• A 5-year average of $94.7 million and a median of $88.4 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 62.75% — and 2025, when it slumped 44.76%.
• Travere Therapeutics' Accumulated Expenses stood at $95.7 million in 2022, then increased by 24.28% to $119.0 million in 2023, then decreased by 27.7% to $86.0 million in 2024, then soared by 46.5% to $126.0 million in 2025, then dropped by 17.16% to $104.4 million in 2026.
• Business Quant data shows TVTX's Accumulated Expenses at $104.4 million in Q1 2026, $126.0 million in Q4 2025, and $105.8 million in Q3 2025.